Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Non Operating Income (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Non Operating Income for 15 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 34.27% to -$2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.5 million through Dec 2025, up 9.28% year-over-year, with the annual reading at -$1.5 million for FY2025, 9.28% up from the prior year.
  • Non Operating Income for Q4 2025 was -$2.2 million at Gyre Therapeutics, down from $727000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $727000.0 in Q3 2025, with the low at -$2.2 million in Q4 2025.
  • Average Non Operating Income over 5 years is -$232444.4, with a median of -$18500.0 recorded in 2021.
  • Peak annual rise in Non Operating Income hit 3600.0% in 2023, while the deepest fall reached 133200.0% in 2023.
  • Over 5 years, Non Operating Income stood at -$20000.0 in 2021, then surged by 95.0% to -$1000.0 in 2022, then plummeted by 23600.0% to -$237000.0 in 2023, then tumbled by 589.45% to -$1.6 million in 2024, then crashed by 34.27% to -$2.2 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$2.2 million, $727000.0, and -$145000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.